This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Hims & Hers Health plans to sell compounded versions of Novo Nordisk’s popular weight loss drug Wegovy to patients in certain professions for $99 a month , Reuters says. Compounded GLP-1 injections are fulfilled and shipped from Hims & Hers affiliated pharmacies and are regulated by the FDA.
percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. by 2029 appeared first on European Pharmaceutical Review. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.
billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01 per cent from 2021 to 2030.
billion in 2030 at a compound annual growth rate (CARG) of 4.6 The market for multiple sclerosis (MS) disease-modifying therapies (DMT) is set to experience moderate growth across the seven major markets (7MM*) from $18.9 billion in 2020 to $29.8 per cent, forecasts GlobalData. bn by 2030: GlobalData appeared first on Express Pharma.
GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.
In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.
He said ensifentrine will “change the treatment paradigm” for COPD by providing bronchodilation and anti-inflammatory properties in one compound. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5
Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1
The sheer number of treatment candidates moving through the pipeline has seen a recent report by Polaris Market Research predicts that the market will grow at a compound annual growth rate of 17.0% from 2021 to 2029. FDA backing.
According to GlobalData’s patient-based forecasts, infliximab biosimilars were anticipated to grow a notable compound annual growth rate (CAGR) of 14% from 2019 to 2029 in Remicade’s leading immunology indications, CD and UC.
Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. A “specified drug” means, for 2021, an applicable drug that is produced, prepared, propagated, compounded, converted, or processed by a specified manufacturer.
in 2029 , with a compound annual growth rate of 27.9%. Life sciences companies can use AI to analyze vast amounts of data and identify drug targets, design small molecules, generate synthesis pathways for chemical compounds, and predict drug properties. The global market for AI in life sciences is projected to reach $33.5b
The amyotrophic lateral sclerosis (ALS) market across the 8MM (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) is projected to grow at a compound annual growth rate (CAGR) of 15 per cent from $317 million in 2019 to $1.28 billion in 2029, forecasts GlobalData.
billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). billion in sales in 2029. billion in sales in 2029. billion in sales in 2029. bn in 2029: GlobalData appeared first on Express Pharma. SPL-026 is also a small-molecule drug. The post Psychedelic drug market to reach $7.2
In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.
billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. billion in 2029, although its sales growth is likely to continue beyond 2029. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9
The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 billion by 2029 (3). Courtesy of contract research organisations (CROs), contract manufacturing organisations (CMOs), and contract development and manufacturing organisations (CDMOs), India’s life sciences sector is rising steadily. billion by 2030 (2).
billion in 2029 at a compound annual growth rate (CAGR) of 7.9 Molecular spectroscopy As one of the main types of spectroscopy technology, the molecular spectroscopy marke t is anticipated to expand at a compound annual growth rate (CAGR) of 9.1 It will grow to $31.77 percent between 2024 and 2025.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content